Genetically modified tumour vaccines - Where we are today

Cancer Treatment Reviews

Volumn 25, Issue 1, 1999, Pages 29-46

  Nawrocki, S ^a   Mackiewicz, A ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Antitumour immune response; Cytokines; Gene therapy of cancer; Tumour antigens; Tumour vaccines

Indexed keywords

B7 ANTIGEN; CYTOKINE; HEAT SHOCK PROTEIN; HLA ANTIGEN; IMMUNOLOGICAL ADJUVANT; TUMOR ANTIGEN; TUMOR VACCINE; VIRUS ANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CANCER CELL; CANCER IMMUNIZATION; CELL LYSATE; CELL MEDIATED CYTOTOXICITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENETICS; HELPER CELL; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; MELANOMA; REVIEW;

EID: 0033080809     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1998.0104     Document Type: Review

References (112)

1. Greenberg PD. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281-355
2. Schreiber H, Ward PL, Rowley DA, Stauss HJ. Unique tumor-specific antigens. Ann Rev Immunol 1988;6:465-483
3. Greenberg PD, Cheever MA, Fefer A. H-2 restriction of adoptive immunotherapy of advanced tumors. J Immunol 1981;126:2100-2103
4. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-1321
5. Shimizu K, Shen FW. Role of different T cell set in the rejection of syngeneic chemically induced tumors. J Immunol 1979;122:1162-1165
6. Fitch FW, McKisic MD, Lancki DW, Gajewski TF. Differential regulation of murine T lymphocyte subsets. Annu Rev Immunol 1993;11:29-48
7. Mosmann TR. Cytokine secretion patterns and cross-regulation of T cell subsets. Immunol Res 1991;10:183-188
8. Romagnani S. Human TH1 and TH2 subsets: Regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 1992;98:279-285
9. Swain SL. CD4 T cell development and cytokine polarisation: An overview. J Leukoc Biol 1995;57:795-798
10. Robey E, Allison JP. T-cell activation: Integration of signals from the antigen receptor and costimulatory molecules. Immunol Today 1995;16:306-310
11. Azuma M, Lanier LL. The role of CD28 costimulation in the generation of cytotoxic T lymphocytes. Curr Top Microbiol Immunol 1995;198:59-74
12. Cohn M. The wisdom of hindsight. Annu Rev Immunol 1994;12:1-62
13. Janeway CA, Jr., Bottomly K. Signals and signs for lymphocyte responses. Cell 1994;76:275-285
14. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994;15:321-331
15. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: Expression and function. J Exp Med 1994;180:631-640
16. Hart DN, Starling GC, Calder VR, Fernando NS. B7/BB1 is a leukocyte differentiation antigen on human dendritic cells induced by activation. Immunology 1994;79:616-620
17. Krummel RF, Allison JP. CD28 and CTLA-4 deliver opposing signals which regulate the response of T cells to stimulation. J Exp Med 1995;182:459-466
18. King CL, Stupi RJ, Craighead N, June CH, Thypronitis G. CD28 activation promotes TH2 subset differentiation by human CD4+ cells. Eur J Immunol 1995;25:587-595
19. Maraveyas A, Hrouda D, Dalgleish AG. Tumor immunology. In: Mackiewicz A, Sehgal PB. Molecular Aspects of Cancer and its Therapy. Basel: Birkhauser, 1998;73-87
20. Chen L, McGowan P, Ashe S et al. Tumor immunogenicity determines the effect of B7 co-stimulation on T-cell mediated tumor immunity. J Exp Meed 1994;179:523-532
21. Chen L, Ashe B, Brady WA et al. Co-stimulation of anti-tumor immunity by the B7 counter receptor for the T-lymphocytes molecules CD28 and CTLA-4. Cell 1992;71:1093-1102
22. Townshead SE, Allison JP. Tumor rejection after direct co-stimulation of the CD8+ cells by B7 transfected melanoma cells. Science 1993;259:368-370
23. Yang G, Hellstrom KE, Hellstrom I, Chen L. Anti-tumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 co-stimulatory molecules. J Immunol 1995;154:2794-2800
24. Chong H, Hutchinson G, Hart IR, Vile RG. Expression of co-stimulatory molecules by tumor cells decreases tumorogenicity but may also reduce anti-tumor immunity. Human Gene Ther 1996;7:1771-1779
25. Becker JC, Brablets T, Czerny C, Teermeer C, Brocker EB. Tumor escape mechanisms from immunosurveillance in a specific MHC-restricted CD4+ human T-cell clone by the autologous MHC class-II melanoma. Int Immunol 1993;5:1501-1508
26. Fearon ER. II-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell 1990;60:3539-3543
27. Shiku H, Takahasi T, Oettgen HF and al. Cell surface antigens of human malignant melanoma. J Exp Med 1976;144:873-881
28. Koprowski H, Steplewski Z, Herlyn D et al. Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci USA 1978;75:3405-3409
29. Herlyn M, Menrad A, Koprowski H, Structure, function, and clinical significance of human tumor antigens. JNCI 1990;82:1883-1889
30. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647
31. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-1457
32. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-352
33. Bakker AB, Schreurs MW, de Boer AJ, et al. Melanocyte lineage-specific antigen gp 100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179:1005-1009
34. Van der Bruggen P, Szikora JP, Boel P, et al. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanoma as expressing HLA-Cw*1601. Eur J Immunol 1994;24:2134-2140
35. Brasseur F, Marchand M, Vanwijck R, et al. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. (letter). Int J Cancer 1992;52:839-841
36. Eckels DD. Alloreactivity: Allogeneic presentation of endogenous peptide or direct recognition of MHC polymorphism?: A review. Tiss Antigens 1990;35:49-75
37. Boel P, Wildmann C, Sensi ML, et al. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-175
38. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-698
39. Topalian SL, Rivoltini L, Mancini M, et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994;91:9461-9465
40. Topalian SL, Rivoltini L, Mancini M, Ng J, Hartzman RJ, Rosenberg SA. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int J Cancer 1994;58:69-79
41. Sahin UO, Tureci H, Schmitt B et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci 1995;92:11810-11813
42. Jager E, Chen Y, Drijfhout J et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1:Definition of human HLA-A2 binding peptide epitopes. J Exp Med 1998;187:265-270
43. Srivastava PK, DeLeo AB, Old LJ et al. Tumor rejection antigens of chemically induced tumors in inbred mice. Proc Natl Acad Sci USA 1986, 83:3407-3411
44. Tamura Y, Tsuboi N, Sato N et al. 70 kD heat shock cognate protein is a transformation associated antigen and a possible target for host's anti-tumor immunity. J Immunol, 1993, 151:5516-5524
45. Srivastava PK, Udono H. Heat shock protein-complexes in cancer immunotherapy, Current Opinion in Immunology, 1994;6:728-732
46. Ressing ME, Sette A, Brandt RM, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A *0201-binding peptides. J Immunol 1995;154:5934-5943
47. Ressing ME, van Driel WJ, Celis E, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A 0201-restricted E7-encoded epitope. Cancer Res 1996;56:582-588
48. Kast WM, Brandt RM, Sidney J, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994;152:3904-3912
49. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy see comments]. N Engl J Med 1995;332:143-149
50. Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84:2221-2228
51. Zea AH, Curti BD, Alvord WG, et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clinical Canc Res 1996;1:1327-1337
52. Ghosh P, Komschlies KL, Cippitelli M, et al. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 1995;87:1478-1483
53. Ochoa AC, Longo DL. Alteration of signal transduction in T cells from cancer patients. Important Adv Oncol 1995;43-54
54. Restifo NP, Kawakami Y, Marincola F, et al. Molecular mechanisms used by tumors to escape immune recognition: Immunogenetherapy and the cell biology of major histocompatibility complex class I. J Immunother 1993;14:182-190
55. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-272
56. Garrido F, Cabrera T, Concha A et al. Natural history of HLA expression during tumor development. Immunol Today 1993;14:491-499
57. Nagata S, Suda T. Fas and fas ligand: Ipr and mutations. Immunol Today 1995;16:39-43
58. Galle PR, Hoffman WJ, Walczak K. Involvment of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995;182:1223-1230
59. Strand S, Hofmann WJ, Hug H et al. Lymphocyte apoptosis induced by CD 95 (APO-1/CD95) ligand - expressing tumor cells - a mechanism of immune evasion. Nature Med 1996;2:1361-1366
60. Hahne M, Rimoldi D. Schroter M et al. Melanoma cell expression of fas ligand: Implications for tumor immune escape. Science 1996;274:1363-1366
61. Walker P. Saas P, Dietrich PY. Role of fas ligand in immune escape. J Immunol 1997;158:4521-4524
62. Livingston P. Overview. In: Bystryn JC, Ferrone S, Livingston P. Specific Immunotherapy of cancer with vaccines. Ann NY Acad Sci 1993;690:1-5
63. Berd D, Maguire HC, Jr., Mastrangelo MJ. Induction of cellmediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986;46:2572-2577
64. Berd D, Maguire HC, Jr., McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858-1867
65. Morton DL, Hoon DS, Nizze JA, et al. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann NY Acad Sci 1993;690:120-134
66. Morton DL, Foshag LJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine published erratum appears in Ann Surg 1993 Mar; 217(3): 309]. Ann Surg 1992;216:463-482
67. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988;48:5883-5893
68. Mitchell MS, Harel W, Kempf RA, et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990;8:856-869
69. Mitchell MS, Harel W, Kan-Mitchell J, et al. Active specific immunotherapy of melanoma with allogeneic cell lysates: Rationale, results, and possible mechanisms of action. Ann NY Acad Sci 1993;690:153-166
70. Bystryn JC. Clinical activity of a polyvalent melanoma antigen vaccine. Recent Results Cancer Res 1995;139:337-348
71. Bystryn JC. Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens. Ann NY Acad Sci 1993;690:190-203
72. Bystryn JC, Oratz R, Roses D, Harris M, Henn M, Lew R. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 1992;69:1157-1164
73. Livingston PO, Kaelin K, Pinsky CM, Oettgen HP, Old LJ. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines. Cancer 1985;56:2194-2200
74. Livingston PO, Ritter G, Srivastava P, et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989;49:7045-7050
75. Helling F, Zhang S, Shang A, et al. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995;55:2783-2788
76. Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight- melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res 1994;54:415-421
77. Mittelman A, Wang X, Matsumoto K, Ferrone S. Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma 1995;14:175-181
78. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992;89:466-470
79. Chen L, Chen D, Manome Y et al. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 1995;96:2775-2782
80. Ido A, Nakata K, Kato Y et al. Gene therapy for hepatoma cells using a retrvirus vector carrying herpes simplex virus thymidyne kinase gene under the control of human alpha-phetoprotein gene promoter. Cancer Res 1995;55:3105-3109
81. Wiznerowicz M, Rose-John S, Mackiewicz A. Gene therapy of cancer. In: Mackiewicz A, Sehgal PB. Molecular Aspects of cancer and its therapy. Basel: Birkhauser 1998;107-150
82. Gansbacher B. Retroviral vector mediated gamma interferon gene transfer into tumor cells generates potential and long-lasting anti-tumor immunity. Cancer Res 1990;50:77820-7825
83. Golumbek P. Controlled release, biodegradable cytokine depots: A new approach in cancer vaccine design. Cancer Res 1993;53:5841-5844
84. Asher AL. Murine tumors cells transfected with the gene for TNF-alfa. J Immunol 1991;146:3227-3234
85. Blankenstein T, Tumor suppression after tumor cell-targeted tumor necrosis factor alfa genetic transfer. J Exp Med 1991;173:1047-1052
86. Hock H, IL-7 induces CD4+ T cell dependent tumor rejection. J Exp Med 1991;174:1291-1298
87. Dranoff G, Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci 1993;90:3539-3543
88. Porgador A, IL-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992;52:3679-3686
89. Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S. Complex of soluble human IL-6 receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 1992;149:2021-2027
90. Mackiewicz A, Wiznerowicz M, Roeb E, Karczewska A, Nowak J, Heinrich P.C, Rose-John S. Soluble interleukin-6 receptor is biologicaly active in vivo. Cytokine 1995;7:142-14
91. Mackiewicz A, Górny A, Laciak M et al. Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with alogenic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Hum Gene Ther 1995;6:805-811
92. Mackiewicz A, Wiznerowicz M, Roeb E et al. Interleukin 6-type cytokines and their receptors for gene therapy of melanoma. Ann NY Acad Sci 1995;762:361-374
93. Rosenberg SA, Lotze MT, Yang JC at al. Prospective randomised trials of high-dose interleukin-2 alone or in conjunction with limfokine-activated tumor killer cells for the treatment of patients with advanced cancer. J Nat Cancer Inst 1993;85:622-632
94. Aebersold P, Hyatt C, Johnson et al. Lysis of autologous melanoma cells by tumor infiltrating lymphocytes: Association with clinical response. J Nat Cancer Inst 1991;83:932-937
95. Nerrouche Y, Negrier S, Bain C et al. Clinical application of retroviral gene transfer in oncology: Results of a french study with tumor infiltrating lymphocytes transduced with the gene of resistance to neomycin. J Nat Cancer Inst 1995;87:280-285
96. Nabel GJ, Nabel EG, Yang ZY et al. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity. Proc Natl Acad Sci 1993;90:11307-11311
97. Rubin J, Charboneau JW, Reading C et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer. Hum Gene Ther 1994;5:1385-1399
98. Stopeck AT, Hersh EM, Apokoriaye ET at al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patient with metastatic melanoma. J Clin Oncol 1997;15(1):341-349
99. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide or tumor lystae-pulsed dendritic cells. Nat Med 1998;4(3):328-332
100. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant andenovirus encoding a model tumor-associated antigen. J Immunol 1996;156:224-231
101. Zhai Y, Yang JC, Kawakami Y, et al. Antigen-specific tumor vaccines: Development and characterization of recombinant adenovirus encoding MART-1 or gp100 for cancer therapy. J Immunol 1996;156:700-710
102. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunlogic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4(3):321-327
103. Kantor J, Irvine K, Abrams S, et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 1992;52:6917-6925
104. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine see comments]. J Natl Cancer Inst 1992;84:1084-1091
105. Kaufman H, Schlom J, Kantor J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int J Cancer 1991;48:900-907
106. Hamilton JM, Chen AP, Nguyen B, et al. Phase I study of recombinant vaccinia virus that expresses human carcinoembryonic antigen in adult patients with adenocarcinomas. Proc Am Soc Clin Oncol 1994;13:295-296
107. Salgaller ML, Bei R, Schlom J, Poole DJ, Robbins PF. Baculovirus recombinants expressing the human carcinoembryonic antigen gene. Cancer Res 1993;53:2154-2161
108. Conry RM, LoBuglio AF, Kantor J, et al. Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res 1994;54:1164-1168
109. Bei R, Kantor J, Kashmiri SV, Abrams S, Schlom J. Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA. J Immunother Emphasis Tumor Immunol 1994;16:275-282
110. Samuel J, Longenecker BM. Development of active specific immunotherapeutic agents based on cancer-associated mucins. Pharm Biotechnol 1995;6:875890
111. Longenecker BM, Reddish M, Koganty R, MacLean GD. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialy1-Tn, an epitope with possible functional significance in metastasis. Adv Exp Med Biol 1994;353:105-124
112. Wiley J. wiley genetic medicine clinical trials database, http://www.wiley.co.uk